The subscription period in AlzeCure Pharma AB's rights issue begins today and the CEO has participated in a company presentation and CEO interview with Erik Penser Bank

AlzeCure Pharma AB (publ) (”AlzeCure” eller ”Bolaget”), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the subscription period in the Company’s capital raising begins today and runs until December 20, 2022. Due to this, AlzeCure wants to inform that Erik Penser Bank has published a company presentation and an interview with the Company's CEO, Martin Jönsson. The company presentation purpose is to give shareholders and other interested parties an insight into the Company's operations and future plans as well as the Company's ongoing rights issue.

The company presentation is uploaded on Erik Penser Bank's YouTube channel and can be viewed through this link: https://youtu.be/g-8yDDnw3kU

The interview is uploaded on Erik Penser Bank's YouTube channel and can be viewed through this link: https://youtu.be/BsWd6SGvBPw

The company presentation and interview are also available on AlzeCure’s website: https://www.alzecurepharma.se/en/presentations-and-interviews/